---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040894"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:05:23.755586+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IDEAYA Q2 net loss $27.9M, cash $510.1M; starts Phase 2/3 registrational trial for darovasertib

## Summary
- Net loss of $27.9M for Q2 2023; accumulated deficit $287.0M; cash and securities $510.1M, funding into 2027.
- Initiated Phase 2/3 registrational trial for darovasertib/crizotinib in first-line HLA-A2(-) metastatic uveal melanoma.
- First patient dosed in Amgen-sponsored Phase 1/2 trial of IDE397 (MAT2A) + AMG 193 in MTAP-deletion solid tumors.
- Anticipating FDA IND clearance in Q3 2023 for GSK101 Pol Theta Helicase inhibitor; $7M milestone due from GSK.
- Targeting Werner Helicase development candidate with GSK in H2 2023, with potential $3M milestone from GSK.

## SEC filing metadata
- accession: 0000950170-23-040894
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000095017023040894/0000950170-23-040894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000095017023040894/idya-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040894
- JSON: https://secwatch.observer/filing/0000950170-23-040894.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040894.txt

## Key facts
- Earnings Releases
  IDEAYA Biosciences, Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1676725/000095017023040894/0000950170-23-040894-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.